Adicon Holdings Ltd
Company Profile
Business description
Founded in 2004 and listing on the Hong Kong Exchange in 2023, Adicon is one of the independent clinical laboratories in China. In October 2018, private equity Carlyle Group completed its investment in Adicon and has since been the large single shareholder. Following Carlyle’s investment, Adicon quickly stepped up its footprint. It has a testing portfolio of over 4,000 medical diagnostic tests with 34 self-operated laboratories in 2024, compared with 1,800 items and 21 labs in 2018. Currently, esoteric tests account for nearly 60% of its testing portfolio. Esoteric tests require more specialized technologies and/or equipment.
Contact
No. 208, Zhenzhong Road
West Lake
Zhejiang
Hangzhou
CHNT: +86 57187779340
Sector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
31 December 2026
Employees
5,071
Stocks News & Analysis
stocks
Strong guidance from undervalued ASX share
stocks
TSMC earnings: Refining guidance and expansion plans amid strong AI demand
stocks
Unconventional wisdom: A top performing ‘AI share’ accidently ended up in my portfolio
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,130.70 | 31.40 | -0.34% |
| CAC 40 | 8,425.13 | 0.00 | 0.00% |
| DAX 40 | 24,702.24 | 547.77 | 2.27% |
| Dow JONES (US) | 49,447.43 | 868.71 | 1.79% |
| FTSE 100 | 10,667.63 | 77.64 | 0.73% |
| HKSE | 26,160.33 | 233.93 | -0.89% |
| NASDAQ | 24,468.48 | 365.78 | 1.52% |
| Nikkei 225 | 58,861.64 | 385.74 | 0.66% |
| NZX 50 Index | 12,950.19 | 44.52 | 0.34% |
| S&P 500 | 7,126.06 | 84.78 | 1.20% |
| S&P/ASX 200 | 8,912.20 | 27.50 | -0.31% |
| SSE Composite Index | 4,051.43 | 4.12 | -0.10% |